GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Chimeric Therapeutics CHM.AX · AUD

Health Care · ASX · 🇦🇺 Australia

Compare

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in AUD, from our data supplier.

FY2026

Revenue

—

FY2020FY2026

Net income

−A$18.8m

FY2020FY2026

Free cash flow

−A$21.6m

FY2020FY2026

Shareholders' equity

−A$7.7m

FY2020FY2026

Income statement

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020
Revenue—A$4.0mA$7.5mA$4.5mA$2.6mA$2,646—
Research and developmentA$3.4mA$9.8mA$10.1mA$13.5mA$5.2mA$3.8m—
Operating income−A$8.4m−A$15.1m−A$12.3m−A$29.6m−A$15.1m−A$15.1m−A$64,010
Net income−A$18.8m−A$10.4m−A$12.5m−A$25.9m−A$15.9m−A$15.1m−A$64,007
Diluted earnings per share-0.61-0.32-1.25-4.65-3.72-4.34-0.00

Balance sheet

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020
Total assetsA$1.3mA$21.6mA$15.3mA$22.4mA$34.9mA$36.5mA$100
Cash and short-term investmentsA$800,145A$5.8mA$3.1mA$5.4mA$18.4mA$22.4mA$100
Total liabilitiesA$9.0mA$19.6mA$12.8mA$16.7mA$9.2mA$11.4mA$64,007
DebtA$679,845—A$3.6m——A$3.7mA$34,007
Shareholders' equity−A$7.7mA$2.0mA$2.5mA$5.7mA$25.7mA$25.1m−A$63,908
Shares outstanding31m33m10m6m4m3m343m

Cash flow

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020
Cash from operations−A$10.8m−A$7.3m−A$7.5m−A$16.3m−A$13.2m−A$8.8m−A$34,007
Capital spending−A$10.8m−A$1−A$7.5m−A$112,193−A$537,855−A$5.3m−A$16,260
Free cash flow−A$21.6m−A$7.3m−A$15.1m−A$16.4m−A$13.7m−A$14.1m−A$50,267
Dividends paid———−A$2.3m−A$4.0m——

Latest quarters

By quarter end

Jun 2026Dec 2025Jun 2025Dec 2024Jun 2024Mar 2024Dec 2023Sept 2023
Revenue——A$3.6mA$5.6m−A$1.8m−A$1.8mA$5.5mA$5.5m
Operating income−A$4.1m−A$3.9m−A$12.5m−A$2.7m−A$11.5m−A$7.5m−A$9.2mA$878,583
Net income−A$7.6m−A$11.2m−A$3.8m−A$2.9m−A$15.0m−A$7.5mA$2.4mA$1.2m
Diluted earnings per share-0.25-0.34-0.12-0.28-1.49-0.740.440.22
Cash from operations−A$6.0m−A$3.0m−A$2.0m−A$1.0m−A$2.0m−A$1.0m−A$4.0m−A$2.0m
Capital spending−A$6.0m———−A$5.0m—−A$4.0m—
Free cash flow−A$12.0m———−A$7.0m—−A$8.0m—
Total assetsA$1.3mA$5.9mA$21.6mA$18.7mA$15.3mA$15.3mA$26.7mA$26.7m
Cash and short-term investmentsA$800,145A$2.5mA$5.8mA$5.1mA$3.1mA$3.1mA$3.5mA$3.5m
DebtA$679,845—A$5.0mA$2.5mA$6.3m—A$2.6m—
Shareholders' equity−A$7.7m−A$3.0mA$2.0mA$5.9mA$2.5mA$2.5mA$13.9mA$13.9m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income-34.4%-11.2%—
Net income-10.1%4.5%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021
Price to earnings-0.2-0.1-0.1-0.3-0.7
Price to sales0.50.20.51.6—

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.